Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
about
Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia.Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.Conivaptan therapy in an infant with severe hyponatremia and congestive heart failureHypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependentCurrent and future G protein-coupled receptor signaling targets for heart failure therapyTolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.Hyponatremia: an update on current pharmacotherapy.Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failureTolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.Deciphering the Relationship between Obesity and Various Diseases from a Network Perspective.Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy.
P2860
Q34107621-9E4343EE-BEE2-444B-812D-9F74B0A5B9FDQ34257617-873744FB-C5A6-42AE-873A-0DA5A7623679Q36289518-61B56CA4-CAA0-4032-939F-204F34ABFA0DQ36838219-51083F3D-18BF-49A1-9964-5E17F8A295A5Q37232104-00510281-5548-4BF5-815D-710860933DDBQ37959051-2D0A82DE-1993-40DB-BFF3-20B274C3A18AQ38089919-5C88A0DE-A96E-4416-B6C2-D97B93BA9097Q39313604-06B1379E-90AD-4161-829D-E3D6F7994645Q39456742-FC160975-1858-4C2D-9296-DB5B4CF9F30BQ40508135-BC994864-5770-4728-A74B-98825DB5CF26Q43988768-71245FFC-B4F3-4ADB-923C-390E69F0150EQ44365732-F3AB703C-A045-404B-9330-035376906AF3Q45107672-F27B1900-28F4-4EDB-805E-1F338EE3753DQ47234369-B8C2EF8F-B293-4843-9D23-34C0CF8E8FFDQ51211871-33C48BE6-945D-4182-8B16-9294B0026302
P2860
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@en
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@nl
type
label
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@en
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@nl
prefLabel
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@en
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@nl
P2093
P2860
P921
P1476
Arginine vasopressin (AVP) and ...... tic hormone secretion (SIADH).
@en
P2093
Amir M Nia
Mariam Semmo
Nasser Semmo
Natig Gassanov
P2860
P2888
P304
P356
10.1007/S00228-011-1006-7
P577
2011-02-17T00:00:00Z